Evaluation of Calcium Gluconate to Reduce Blood Loss During Elective Cesarean Delivery

What this Trial Is About

Postpartum hemorrhage PPH is the leading cause of death related to pregnancy, often resulting in severe complications such as blood transfusion, coagulation disorders, hysterectomy, or death. This trial evaluates whether administering calcium gluconate during the third stage of elective Cesarean delivery can reduce blood loss by lowering uterine atony and coagulopathy risks, addressing the ongoing high rates of PPH despite existing treatments. Participants will receive either 10 ml of 10% calcium gluconate diluted in saline or a placebo of normal saline intravenously after umbilical cord clamping, in addition to Carbetocin, a long-acting oxytocin analogue. The study uses a randomized, double-blind, parallel design with treatment allocation alternating by month. Blood samples and ECG monitoring are used to ensure safety and eligibility, excluding women with abnormal calcium levels or QT abnormalities. During the study, participants undergo blood gas analysis, coagulation profiles, and hemoglobin level monitoring before and after surgery, with follow-up blood tests the next day. Researchers will measure the change in hemoglobin levels 24 hours post-surgery as the primary outcome, along with secondary outcomes like blood loss during surgery, need for additional therapies, blood transfusions, hospitalization length, and adverse maternal events. The study aims to monitor safety and efficacy throughout hospitalization and track outcomes over an average of four days.

Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery